Preserved learning and memory in mice following chemotherapy: 5-Fluorouracil and doxorubicin single agent treatment, doxorubicin-cyclophosphamide combination treatment

Behavioural Brain Research

Volumn 226, Issue 1, 2012, Pages 154-162

  Fremouw, Thane ^a,b   Fessler, Christy L ^a   Ferguson, Robert J ^c   Burguete, Yamil ^a  

^a University of Maine   (United States)

^b UNIVERSITY OF MAINE   (United States)

^c EASTERN MAINE MEDICAL CENTER   (United States)

Author keywords

Chemo brain; Chemo fog; Chemotherapy; Contextual fear conditioning; Leaning; Memory; Novel object recognition

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ANIMAL EXPERIMENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COGNITION; COGNITIVE DEFECT; CONTEXTUAL FEAR CONDITIONING; CONTROLLED STUDY; DRUG MEGADOSE; EXPLORATORY BEHAVIOR; FEAR; FEMALE; LEARNING; LOCOMOTION; MALE; MEMORY; MONOTHERAPY; MOUSE; NONHUMAN; OBJECT RECOGNITION; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; COGNITION DISORDERS; CONDITIONING, CLASSICAL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEAR; FLUOROURACIL; MICE; RECOGNITION (PSYCHOLOGY);

EID: 80053352445     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.09.013     Document Type: Article

References (76)

1. van Dam F.S., Schagen S.B., Muller M.J., Boogerd W., vd Wall E., Droogleever Fortuyn M.E., et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998, 90:210-218.
2. Vardy J., Tannock I. Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol 2007, 63:183-202.
3. Falleti M.G., Sanfilippo A., Maruff P., Weih L., Phillips K.A. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005, 59:60-70.
4. Jansen C.E., Miaskowski C., Dodd M., Dowling G., Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005, 104:2222-2233.
5. Stewart A., Bielajew C., Collins B., Parkinson M., Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006, 20:76-89.
6. Ferguson R.J., Ahles T.A. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep 2003, 3:215-222.
7. Tannock I.F., Ahles T.A., Ganz P.A., Van Dam F.S. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004, 22:2233-2239.
8. Ahles T.A., Saykin A.J., Furstenberg C.T., Cole B., Mott L.A., Titus-Ernstoff L., et al. Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J Clin Oncol 2005, 23:4399-4405.
9. Stanton A.L. Psychosocial concerns and interventions for cancer survivors. J Clin Oncol 2006, 24:5132-5137.
10. Raffa R.B. Short introduction and history. Adv Exp Med Biol 2010, 678:1-10.
11. Taillibert S. Is systemic anti-cancer therapy neurotoxic? Does chemo brain exist? And should we rename it?. Adv Exp Med Biol 2010, 678:86-95.
12. Donovan K.A., Small B.J., Andrykowski M.A., Schmitt F.A., Munster P., Jacobsen P.B. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 2005, 104:2499-2507.
13. Phillips K.A., Bernhard J. Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 2003, 95:190-197.
14. Schagen S.B., van Dam F.S., Muller M.J., Boogerd W., Lindeboom J., Bruning P.F. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999, 85:640-650.
15. Castellon S.A., Ganz P.A., Bower J.E., Petersen L., Abraham L., Greendale G.A. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004, 26:955-969.
16. Hermelink K., Untch M., Lux M.P., Kreienberg R., Beck T., Bauerfeind I., et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007, 109:1905-1913.
17. Jenkins V., Shilling V., Deutsch G., Bloomfield D., Morris R., Allan S., et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006, 94:828-834.
18. Scherwath A., Mehnert A., Schleimer B., Schirmer L., Fehlauer F., Kreienberg R., et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 2006, 17:415-423.
19. Wefel J.S., Kayl A.E., Meyers C.A. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 2004, 90:1691-1696.
20. Ahles T.A., Silberfarb P.M., Herndon 2nd J., Maurer L.H., Kornblith A.B., Aisner J., et al. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J Clin Oncol 1998, 16:1954-1960.
21. Meyers C.A., Albitar M., Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104:788-793.
22. Seigers R., Fardell J.E. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev 2011, 35:729-741.
23. Walker E.A. Animal models. Adv Exp Med Biol 2010, 678:138-146.
24. Yanovski J.A., Packer R.J., Levine J.D., Davidson T.L., Micalizzi M., D'Angio G. An animal model to detect the neuropsychological toxicity of anticancer agents. Med Pediatr Oncol 1989, 17:216-221.
25. Konat G.W., Kraszpulski M., James I., Zhang H-T., Abraham J. Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis 2008, 23:325-333.
26. MacLeod J.E., DeLeo J.A., Hickey W.F., Ahles T.A., Saykin A.J., Bucci D.J. Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res 2007, 181:168-172.
27. Mustafa S., Walker A., Bennett G., Wigmore P.M. 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus. Eur J Neurosci 2008, 28:323-330.
28. ElBeltagy M., Mustafa S., Umka J., Lyons L., Salman A., Chur-yoe G.T., et al. Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil. Behav Brain Res 2010, 208:112-117.
29. Foley J.J., Raffa R.B., Walker E.A. Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology 2008, 199:527-538.
30. Seigers R., Schagen S.B., Beerling W., Boogerd W., van Tellingen O., van Dam F.S., et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008, 186:168-175.
31. Seigers R., Schagen S.B., Coppens C.M., van der Most P.J., van Dam F.S., Koolhaas J.M., et al. Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats. Behav Brain Res 2009, 201:279-284.
32. Winocur G., Vardy J., Binns M., Kerr L., Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006, 85:66-75.
33. Fardell J.E., Vardy J., Logge W., Johnston I. Single high dose treatment with methotrexate causes long-lasting cognitive dysfunction in laboratory rodents. Pharmacol Biochem Behav 2010, 97:333-339.
34. Yang M., Kim J.S., Song M.S., Kim S.H., Kang S.S., Bae C.S., et al. Cyclophosphamide impairs hippocampus-dependent learning and memory in adult mice: Possible involvement of hippocampal neurogenesis in chemotherapy-induced memory deficits. Neurobiol Learn Mem 2010, 93:487-494.
35. Gandal M.J., Ehrlichman R.S., Rudnick N.D., Siegel S.J. A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience 2008, 157:95-104.
36. Lyons L., Elbeltagy M., Bennett G., Wigmore P. The effects of cyclophosphamide on hippocampal cell proliferation and spatial working memory in rat. PLoS ONE 2011, 6:e21445.
37. Walker E.A., Foley J.J., Clark-Vetri R., Raffa R.B. Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice. Psychopharmacology 2011.
38. Lee G.D., Longo D.L., Wang Y., Rifkind J.M., Abdul-Raman L., Mamczarz J.A., et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res 2006, 12:198-205.
39. Dietrich J., Han R., Yang Y., Mayer-Proschel M., Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006, 5:22.
40. Han R., Yang Y.M., Dietrich J., Luebke A., Mayer-Proschel M., Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008, 7:12.
41. Janelsins M.C., Roscoe J.A., Berg M.J., Thompson B.D., Gallagher M.J., Morrow G.R., et al. IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice. Cancer Invest 2010, 28:544-553.
42. Mondie C.M., Vandergrift K.A., Wilson C.L., Gulinello M.E., Weber E.T. The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors in mice. Behav Brain Res 2010, 209:66-72.
43. Li C., Liu D., Huang L., Wang H., Zhang J., Luo X. Cytosine arabinoside treatment impairs the remote spatial memory function and induces dendritic retraction in the anterior cingulate cortex of rats. Brain Res Bull 2008, 77:237-240.
44. Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007, 7:192-201.
45. Froklage F.E., Reijneveld J.C., Heimans J.J. Central neurotoxicity in cancer chemotherapy: pharmacogenetic insights. Pharmacogenomics 2011, 12:379-395.
46. Tubiana-Hulin M., Gardner M. Adjuvant chemotherapy. Cancer Treat Res 2009, 151:121-137.
47. Henderson I.C. Can we abandon anthracyclines for early breast cancer patients?. Oncology (Williston Park) 2011, 25:115-124. 127.
48. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
49. Deng W., Aimone J.B., Gage F.H. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?. Nat Rev Neurosci 2010, 11:339-350.
50. Winters B.D., Saksida L.M., Bussey T.J. Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev 2008, 32:1055-1070.
51. Broadbent N.J., Gaskin S., Squire L.R., Clark R.E. Object recognition memory and the rodent hippocampus. Learn Mem 2010, 17:5-11.
52. Focan C. Circadian rhythms and cancer chemotherapy. Pharmacol Ther 1995, 67:1-52.
53. Anagnostaras S.G., Wood S.C., Shuman T., Cai D.J., Leduc A.D., Zurn K.R., et al. Automated assessment of pavlovian conditioned freezing and shock reactivity in mice using the video freeze system. Front Behav Neurosci 2010, 4.
54. Dix S.L., Aggleton J.P. Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition. Behav Brain Res 1999, 99:191-200.
55. Liedke P.E., Reolon G.K., Kilpp B., Brunetto A.L., Roesler R., Schwartsmann G. Systemic administration of doxorubicin impairs aversively motivated memory in rats. Pharmacol Biochem Behav 2009, 94:239-243.
56. Mignone R.G., Weber E.T. Potent inhibition of cell proliferation in the hippocampal dentate gyrus of mice by the chemotherapeutic drug thioTEPA. Brain Res 2006, 1111:26-29.
57. Jaholkowski P., Kiryk A., Jedynak P., Ben Abdallah N.M., Knapska E., Kowalczyk A., et al. New hippocampal neurons are not obligatory for memory formation; cyclin D2 knockout mice with no adult brain neurogenesis show learning. Learn Mem 2009, 16:439-451.
58. Leuner B., Gould E., Shors T.J. Is there a link between adult neurogenesis and learning?. Hippocampus 2006, 16:216-224.
59. Koehl M., Abrous D.N. A new chapter in the field of memory: adult hippocampal neurogenesis. Eur J Neurosci 2011, 33:1101-1114.
60. Aimone J.B., Deng W., Gage F.H. Adult neurogenesis: integrating theories and separating functions. Trends Cogn Sci 2010, 14:325-337.
61. Trouche S., Bontempi B., Roullet P., Rampon C. Recruitment of adult-generated neurons into functional hippocampal networks contributes to updating and strengthening of spatial memory. Proc Natl Acad Sci U S A 2009, 106:5919-5924.
62. Deng W., Saxe M.D., Gallina I.S., Gage F.H. Adult-born hippocampal dentate granule cells undergoing maturation modulate learning and memory in the brain. J Neurosci 2009, 29:13532-13542.
63. Goodman T., Trouche S., Massou I., Verret L., Zerwas M., Roullet P., et al. Young hippocampal neurons are critical for recent and remote spatial memory in adult mice. Neuroscience 2010, 171:769-778.
64. DeLorey T.M., Handforth A., Anagnostaras S.G., Homanics G.E., Minassian B.A., Asatourian A., et al. Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. J Neurosci 1998, 18:8505-8514.
65. Maren S. Neurotoxic or electrolytic lesions of the ventral subiculum produce deficits in the acquisition and expression of Pavlovian fear conditioning in rats. Behav Neurosci 1999, 113:283-290.
66. Reiriz A.B. Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res 2006, 12:5000-5001.
67. Drew M.R., Denny C.A., Hen R. Arrest of adult hippocampal neurogenesis in mice impairs single-but not multiple-trial contextual fear conditioning. Behav neurosci 2010, 124:446-454.
68. Denny CA, Burghardt NS, Schachter DM, Hen R, Drew MR. 4- to 6-week-old adult-born hippocampal neurons influence novelty-evoked exploration and contextual fear conditioning. Hippocampus 2011; doi:10.1002/hipo.20964.
69. Clark P.J., Kohman R.A., Miller D.S., Bhattacharya T.K., Brzezinska W.J., Rhodes J.S. Genetic influences on exercise-induced adult hippocampal neurogenesis across 12 divergent mouse strains. Genes Brain Behav 2011, 10:345-353.
70. Kempermann G., Chesler E.J., Lu L., Williams R.W., Gage F.H. Natural variation and genetic covariance in adult hippocampal neurogenesis. Proc Natl Acad Sci U S A 2006, 103:780-785.
71. Kempermann G., Gage F.H. Genetic determinants of adult hippocampal neurogenesis correlate with acquisition, but not probe trial performance, in the water maze task. Eur J Neurosci 2002, 16:129-136.
72. Kempermann G., Gage F.H. Genetic influence on phenotypic differentiation in adult hippocampal neurogenesis. Brain Res Dev Brain Res 2002, 134:1-12.
73. Kempermann G., Kuhn H.G., Gage F.H. Genetic influence on neurogenesis in the dentate gyrus of adult mice. Proc Natl Acad Sci U S A 1997, 94:10409-10414.
74. Aluise C.D., Miriyala S., Noel T., Sultana R., Jungsuwadee P., Taylor T.J., et al. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radical Biol Med 2011, 50:1630-1638.
75. Aluise C.D., Sultana R., Tangpong J., Vore M., St Clair D., Moscow J.A., et al. Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol 2010, 678:147-156.
76. Wiltgen B.J., Sanders M.J., Anagnostaras S.G., Sage J.R., Fanselow M.S. Context fear learning in the absence of the hippocampus. J Neurosci. 2006, 26(20):5484-5491.